About GALECTIN THERAPEUTICS INC


  • Ticker GALT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,426,000
  • Market Cap $123M
  • Description
  • Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial f...
More about GALT
Track This Portfolio

Track Royal Fund Management, LLC Portfolio

Follow Royal Fund Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Fund Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Royal Fund Management, LLC with notifications on news.